Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  alemtuzumab
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 88 for your search:
Start Over
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: EudraCT:2005-000805-68, NCT00354120
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAM307, NCT00046683
Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAM314, 2004-000149-39, NCT00086580
Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 12 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: PROGAST, NCT00180089
Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000577580, CLL-2007-FMP, RECF0496, INCA-RECF0496, EudraCT-2007-000327-18, NCT00564512
Alemtuzumab and CHOP in T-cell Lymphoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2006-006130-17, NCT00646854
Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CM-2008-01, 08/H0720/15, 74928896, NCT01077908
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 15 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02807, CDR302482, CALGB 10102, U10CA031946, NCT00061945
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: 12472, ACHE, BCM-H-12472, H 12472, BCM-ACHE, NCT00056966
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 0 to 70
Sponsor: Other
Protocol IDs: H8714, DIMSUM, NCT00048412
Fludarabine and PK-Directed Busulfan With or Without ATG Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 55
Sponsor: NCI, Other
Protocol IDs: LCCC 0510, P30CA016086, CDR0000550145, UNC-LCCC-0510, NCT00448357
Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Over 15
Sponsor: Other
Protocol IDs: P051003, NCT00773149
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: MC088C, NCI-2009-00935, 08-008775, NCT00935792
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-0132, NCT00943319
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: 14341B, NCT00943592
Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: AGMT CLL-6 BendAlem, NCT00951457
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 16 to 120
Sponsor: Other
Protocol IDs: 090331, NCT00983528
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: LS1084, NCI-2010-02329, 10-003025, NCT01269385
Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: Pro00008771, DUMC-1340-99-7, NCI-G99-1617, CDR0000067374, NCT00004143
Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067506, U10CA031946, CLB-19901, CALGB-19901, NCT00004857
Start Over